Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: Focus on severe infections and tuberculosis

Clinical Rheumatology

Volumn 32, Issue 3, 2013, Pages 293-300

  Hammoudeh, Mohammed ^a   Alarfaj, Abdurhman ^b   Chen, Der Yuan ^c,d   Djoudi, Hachemi ^e   Youseif, Ehab ^f   Zhu, Jian ^g  

^a HAMAD MEDICAL CORPORATION   (Qatar)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e Centre Hospitalier et Universitaire   (Algeria)

^f PFIZER INC   (United States)

^g CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Adalimumab; Ankylosing spondylitis; Etanercept; Infliximab; Rheumatoid; Tuberculosis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR;

AFRICA; ANKYLOSING SPONDYLITIS; ASIA; DATA BASE; EUROPE; FOLLOW UP; HUMAN; INCIDENCE; INFECTION; MIDDLE EAST; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TUBERCULOSIS;

AFRICA; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIA; HUMANS; INFECTION; MIDDLE EAST; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876690945     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2137-7     Document Type: Review

References (50)

1. Lawrence RC, Felson DT, Helmick CG et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26-35
2. Zeng QY, Chen R, Daramawan J et al (2008) Rheumatic diseases in China. Arthritis Res Ther 10:R17
3. Symmons D, Mathers C, Pfleger B (2006) The global burden of rheumatoid arthritis in the year 2000. Working Paper, World Health Organization, Geneva www.who.int/healthinfo/statistics/bod-rheumatoidarthritis.pdf. Accessed 26 Apr 2012
4. Al-Rawi ZS, Alazzawi AJ, Alajili FM, Alwakil R (1978) Rheumatoid arthritis in population samples in Iraq. Ann Rheum Dis 37:73-75
5. Pountain G (1991) The prevalence of rheumatoid arthritis in the Sultanate of Oman. Br J Rheumatol 30:24-28
6. Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229
7. Hukuda S, Minami M, Saito T et al (2001) Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 28:554-559
8. Mijiyawa M, Oniankitan O, Khan MA (2000) Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol 12:281-286
9. Brown MA, Jepson A, Young A, Whittle HC, Greenwood BM, Wordsworth BP (1997) Ankylosing spondylitis in West Africans - evidence for a non-HLA-B27 protective effect. Ann Rheum Dis 56:68-70
10. Amroun H, Djoudi H, Busson M et al (2005) Early-onset ankylosing spondylitis is associated with a functional MICA polymorphism. Hum Immunol 66:1057-1061
11. Younsi R, Azrib S, Aitouazar M, Hari WG, El Hassani S (2007) Evaluation de 'incidence du gène HLA-B27 chez le patient attaint de spondlyarthrite ankylosante au Maroc. Revue de Rhumatisme 74:1013
12. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9:52
13. Braun J, van den Berg R, Baraliakos X et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896-904
14. Raychaudhuri SP, Nguyen CT, Raychaudhuri SK, Gershwin ME (2009) Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 9:67-81
15. Bernatsky S, Habel Y, Rahme E (2010) Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 37:928-931
16. Gliklich RE, Dreyer NA et al (2010) Registries for evaluating patient outcomes: a user's guide. Agency for Healthcare Research and Quality (US), Rockville
17. Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev: CD008794
18. Dixon WG, Symmons DPM, Lunt M et al (2007) Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56:2896-2904
19. United Nations (2009) Tuberculosis prevalence rate per 100,000 population (mid-point) http://data.un.org/Data.aspx?d=MDG&f=seriesRowID%3A617. Accessed 26 Apr 2012
20. Dabbous O, Gilmer K, Tatsuki Y et al (2007) Tuberculosis in Japanese patients with rheumatoid arthritis treated with infliximab: findings from the post marketing surveillance trial. 2007 Annual ACR Meeting
21. Komano Y, Tanaka M, Nanki T et al (2011) Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 38:1258-1264
22. National Technic Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Duanmu H (2002) [Report on fourth national epidemiological sampling survey of tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 25:3-7
23. Hu DW, Bao CD, Chen SL et al (2005) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor-Fc fusion protein: a multicenter, randomized, double blind, controlled trial. Chin J Rheumatol 9:664-668
24. Hou Y, Zhang FC, Huang F et al (2005) Infliximab versus placebo in rheumatoid arthritis receiving concomitant methotrexate: a randomized double blind phase III trial in China. Chin J Rheumatol 10:658-663
25. Huang F, Wang L, Zhang J, Deng X, Guo J, Zhang Y (2006) Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-α antagonists. APLAR J Rheumatol 9:170-174
26. Huang F, Zhang FC, Bao CD et al (2009) Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study. Zhonghua Nei Ke Za Zhi 48:916-921
27. Tam LS, Leung CC, Ying SK et al (2010) Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong - the role of TNF blockers in an area of high tuberculosis burden. Clin Exp Rheumatol 28:679-685
28. Wang LS, Huang F, Zhang JL et al (2007) A cohort analysis of safety tumor necrosis factor- antagonists in the treatment of Chinese patients with ankylosing spondylitis. Chin J New Drugs 16:556-561
29. Chen DY, Chou SJ, Hsieh TY et al (2009) Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J Formos Med Assoc 108:310-319
30. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 59:800-806
31. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF{alpha} inhibitors: the utility of IFNγ assay. Ann Rheum Dis 71:231-237
32. Navarra S, Raso AA, Linchauco JJ, Tan P (2006) Clinical experience with infliximab among Filipino patients with rheumatic diseases. Int J Rheumatic Dis 9:150-156
33. Seong SS, Choi CB, Woo JH et al (2007) Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 34:706-711
34. Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH (2011) Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers. J Rheumatol 38:2218-2223
35. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S (2009) The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Int J Rheum Dis 12:118-124
36. Kumar A (2006) Experience with anti-tumor necrosis factor-α therapy in India. APLAR J Rheumatol 9:141
37. Allali F, Rkain H, Faik A, El Hassani S, Hajjaj-Hassouni N (2005) Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients. Clin Rheumatol 24:656-657
38. El Mansouri L, Bahiri R, Abourazzak FE, Abouqal R, Hajjaj-Hassouni N (2009) Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int 29:1423-1429
39. Public Health Agency of Canada (2011) International tuberculosis incidence rates. http://www.phac-aspc.gc.ca/tbpc-latb/itir-eng.php. Accessed 17 Jul 2012
40. Salmon-Ceron D, Tubach F, Lortholary O et al (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70:616-623
41. Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol (Oxford) 50:124-131
42. Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522-528
43. Greenberg JD, Reed G, Kremer JM et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380-386
44. Carmona L, Gómez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72
45. Al-Ghamdi A, Attar SM (2009) Extra-articular manifestations of rheumatoid arthritis: a hospital-based study. Ann Saudi Med 29:189-193
46. Attar SM, Al-Ghamdi A (2010) Radiological changes in rheumatoid arthritis patients at a teaching hospital in Saudi Arabia. East Mediterr Health J 16:953-957
47. Kazkaz L, Marotte H, Hamwi M et al (2007) Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. Ann Rheum Dis 66:195-201
48. Winthrop KL (2010) The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy. Int J Adv Rheumatol 8:43-52
49. Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34-38
50. Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies Registry. Arthritis Rheum 60:1884-1894